← Leaderboards
Nora M Navone
University Of Texas Md Anderson Can Ctr
$4,341,441
Attributed
$7,091,090
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,091,090 · 4
By mechanism
U01$4,124,474 · 1
P50$1,409,835 · 1
R01$1,323,656 · 1
R29$233,125 · 1
Top collaborators
- Yu Chen4 shared
- Phillip Andrew Futreal4 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Ho-Young Lee$4,801,977
- Funda Meric-Bernstam$12,297,463
- Gabriel Lopez-Berestein$9,617,602
- Susan M Fischer$12,916,650
- Luis A. Martinez$479,032
Others in their field
Top investigators on “Growth”
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$233,131,631
- Albert Lazzarini · California Institute Of Technology$170,110,000
- David H Reitze · University Of Florida$170,110,000
- Garret A Fitzgerald · University Of Pennsylvania$153,184,124
- David Heimbrook · Leidos Biomedical Research, Inc.$143,966,408
- Carol Nesel · Westat$116,355,411
Research focus
GrowthDesignSignal TransductionPathway InteractionsGenesBiological ModelsMalignant Neoplasm Of ProstatePre-ClinicalBasePharmaceutical PreparationsResistanceResponseMalignant NeoplasmsSiteClinical TrialsClinically RelevantClinical ResearchAndrogensXenograft ProcedureBone NeoplasmsGene ExpressionCancer PatientProstateReaction
Grant awards (17)
Patient-Derived Models of Prostate Cancer for Personalized Medicine$1,005,497
U01 · FY2022 · CA · contact PI
Patient-Derived Models of Prostate Cancer for Personalized Medicine$1,026,019
U01 · FY2021 · CA · contact PI
Patient-Derived Models of Prostate Cancer for Personalized Medicine$1,051,939
U01 · FY2020 · CA · contact PI
Patient-Derived Models of Prostate Cancer for Personalized Medicine$1,041,019
U01 · FY2019 · CA · contact PI
Targeting FGF Signaling in Prostate Cancer Progression$268,384
P50 · FY2013 · CA · contact PI
Targeting FGF Signaling in Prostate Cancer Progression$293,695
P50 · FY2012 · CA · contact PI
Targeting FGF Signaling in Prostate Cancer Progression$281,110
P50 · FY2011 · CA · contact PI
Targeting FGF Signaling in Prostate Cancer Progression$283,347
P50 · FY2010 · CA · contact PI
Targeting FGF Signaling in Prostate Cancer Progression$283,299
P50 · FY2009 · CA · contact PI
Cbfa1 and Prostate Cancer Bone Metastases$254,852
R01 · FY2007 · CA · contact PI
Cbfa1 and Prostate Cancer Bone Metastases$262,464
R01 · FY2006 · CA · contact PI
Cbfa1 and Prostate Cancer Bone Metastases$268,780
R01 · FY2005 · CA
Cbfa1 and Prostate Cancer Bone Metastases$268,780
R01 · FY2004 · CA
Cbfa1 and Prostate Cancer Bone Metastases$268,780
R01 · FY2003 · CA
GROWTH REGULATION OF PROSTATIC CELLS BY ANDROGEN$112,015
R29 · FY2001 · CA
GROWTH REGULATION OF PROSTATIC CELLS BY ANDROGEN$108,752
R29 · FY2000 · CA
GROWTH REGULATION OF PROSTATIC CELLS BY ANDROGEN$12,358
R29 · FY2000 · CA